Sugi Predict

Sugi Predict / Compounds / SCHEMBL1487635

SCHEMBL1487635

SCHEMBL1487635

CCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@@H]4O[C@H](CO)[C@H](O)[C@H](O[C@]5(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O5)[C@H]4O)[C@H](O)[C@H]3NC(C)=O)[C@H]2O)[C@H](O)[C@H]1O)NC(C)=O

nearest known ligand 0.59

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ SIGLEC7 Q9Y286 6/20 0.59
▸ MAG P20916 7/20 0.52
▸ SELP P16109 3/20 0.49
▸ SELL P14151 2/20 0.49
▸ SELE P16581 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29652061 1.00 SIGLEC7 (0.59) SIGLEC7MAGSELPSELLSELE
SCHEMBL12313945 0.98 SIGLEC7 (0.62) SIGLEC7MAGSELPSELLSELE
SCHEMBL30652770 0.96 SIGLEC7 (0.57) SIGLEC7MAGSELPSELLSELE
SCHEMBL30651528 0.96 SIGLEC7 (0.57) SIGLEC7MAGSELPSELLSELE
SCHEMBL30650129 0.96 SIGLEC7 (0.57) SIGLEC7MAGSELPSELLSELE
SCHEMBL30650325 0.96 SIGLEC7 (0.57) SIGLEC7MAGSELPSELLSELE
SCHEMBL30650935 0.96 SIGLEC7 (0.57) SIGLEC7MAGSELPSELLSELE
SCHEMBL30655318 0.96 SIGLEC7 (0.57) SIGLEC7MAGSELPSELLSELE
SCHEMBL30655289 0.96 SIGLEC7 (0.57) SIGLEC7MAGSELPSELLSELE
SCHEMBL30653895 0.96 SIGLEC7 (0.57) SIGLEC7MAGSELPSELLSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309186-A1 Metabolomics-Based Identification of Disease-Causing Agents GEORGIA TECH RESEARCH CORPORATION 2014-10-16 — — US disclosed
US-20110246081-A1 Metabolomics-Based Identification of Disease-Causing Agents GEORGIA TECH RESEARCH CORPORATION (US) 2011-10-06 — — US disclosed
US-7902170-B2 Oligosaccharide chain, which contianing a terminal NeuNAc alpha 6 linked to a linear or branched polylcatosamine type structure containing at least 3 lactosamine; a linear or branched structure with two lactosamine and one lactose Biotie Theraples Corp. (FI) 2011-03-08 — — US disclosed
WO-2009052186-A1 METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS GEORGIA TECH RESEARCH CORPORATION (US) 2009-04-23 — — WO disclosed
US-20030181714-A1 Influenza virus binding, sialylated oligosaccharide substance and use thereof KARLSSON, KARL-ANDERS (SE) 2003-09-25 — — US disclosed
EP-1320374-A1 INFLUENZA VIRUS BINDING, SIALYLATED OLIGOSACCHARIDE SUBSTANCE AND USE THEREOF Biotie Therapies Corp. (FI) 2003-06-25 — — EP disclosed
WO-2001097819-A1 INFLUENZA VIRUS BINDING, SIALYLATED OLIGOSACCHARIDE SUBSTANCE AND USE THEREOF CARBION OY (FI) 2001-12-27 — — WO disclosed
Send feedback